Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
Not yet recruiting · NCT07613788 · Registry updated 2026-05-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 2 | 2026-05-29 | NCT07613788 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ruijin Hospital | 454 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | China | 1 |